Shanghai, China, and Chicago, USA, December 23, 2021 - Reistone Biopharma (“Reistone”), a global biotechnology company focused on development of treatments for immune and inflammation related diseases

Dr Irwin Wang, CEO of Reistone Biopharma, shares her motivations behind the establishment of the company, their extremely productive collaboration with Jiangsu Hengrui (China's largest pharma company by market capitalization), and their exciting internati

In October 2018, JAK1 inhibitor SHR0302 of Hengrui Pharmaceutical was approved by FDA to carry out a phase II clinical study for ulcerative colitis; more than one month later, NMPA also approved the clinical trial application